Zolmitriptan

Introduction to acute treatment in migraine

Migraine is a complex brain disorder that causes recurrent episodes involving head pain, nausea, and/or sensitivity to light and sound among other debilitating symptoms. Migraine episodes can last between 4-72 hours when untreated, and are often very disabling.

Migraine treatment is divided into:

• acute: treating the individual migraine episodes
• preventive: aiming to prevent an episode from developing

Both acute and preventive treatment can consist of pharmacological as well as non-pharmacological options. To ensure acute treatment works effectively it is important to choose the appropriate medication, dose, route of administration, and identify the correct time to take it as doses taken early have the best outcomes.

The aim of acute treatment is to (2, 3):

• provide rapid and sustained relief of head pain and the most bothersome symptoms within two hours
• restore functional ability
• minimize rescue medication use 
• reduce side effects

There are a variety of medications available for the acute treatment of migraine, however the same treatment may not work for every person. Finding the right medication depends on having the right diagnosis, any other health conditions or medications, and the severity of your symptoms. (1)

Your doctor can also help you to manage lifestyle triggers and comorbidities. Addressing lifestyle factors is an important early step of treatment, and can ensure you are taking the medication best suited to the severity and frequency of your episodes (4). 

What is zolmitriptan?

Zolmitriptan is part of a class of medications called ‘triptans’, which belong to a group of drugs called serotonin agonists. Triptans were specifically developed as an acute migraine treatment, targeting the underlying processes that cause symptoms during a migraine episode. (5) This sets them apart from other acute treatments such as paracetamol, ibuprofen, or other non-steroidal anti-inflammatory drugs (NSAIDs).

Zolmitriptan can be taken to reduce symptoms when you start to experience a migraine episode. Your doctor may recommend trying zolmitriptan if you do not respond to over-the-counter medications. While triptans may be an effective acute treatment for migraine, it is important to use them in a safe manner both with respect to the number of times they are used per month, or other health conditions.

Zolmitriptan at a glance

Cost and access in Australia

Zolmitriptan tablets are available in Australia for those who are diagnosed with migraine with or without aura. It is available on prescription under Schedule 4 (prescription only).

You are able to purchase 2 packets x 2.5mg tablets (4 tablets total), with a prescription from their doctor.  Zolmitriptan is subsidised under the Pharmaceutical Benefits Scheme (PBS), meaning most people pay around $25.35 per 2‑tablet pack (2 × 2.5 mg) as a general patient, or cheaper if you’re eligible for a concession.

For those paying privately (without PBS), prices vary depending on the brand and pharmacy. The typical cost for a 4‑tablet pack hovers around  $20–$30. (6)

How zolmitriptan works

Zolmitriptan belongs to a class of drugs called ‘triptans’, which are acute medications developed specifically to treat migraine pain and classed as selective serotonin agonists. However, they aren’t ‘painkillers’ in the same way as paracetamol, ibuprofen or non-steroidal anti-inflammatory drugs.

Triptans target the underlying processes that cause migraine symptoms. In the 1990s, researchers discovered that serotonin played a pivotal role in migraine episodes (5). This led to the development of triptans, which selectively activate the 5-HT1B and 5-HT1D receptors (5). This stops two of the processes that occur during a migraine episode:

• Dilation of blood vessels. Dilated blood vessels contribute towards the pain of a migraine episode by the activation of pain nerves, and release of a variety of neuropeptides (pain-causing chemicals).. When the 5-HT1B receptor is activated, it helps to constrict (narrow) your blood vessels. 
• Activation of trigeminovascular system. The trigeminal nerves usually release proinflammatory proteins during a migraine episode, which causes migraine pain. Activation of the 5-HT1D receptor stops these proinflammatory proteins from being released.

Zolmitriptan is only effective for migraine episodes, and can’t be used to treat other conditions or other headache disorders. Triptans also can’t be used to prevent migraine episodes from occurring.

Dosage and administration

Recommended Dose (7)

Zolmitriptan is typically taken as a 2.5 mg tablet at the onset of a migraine, however this may be further discussed with your doctor. . If symptoms return, a second dose can be taken—but not within two hours of the first dose. Do not take more than 10 mg (i.e., four 2.5 mg tablets) in 24 hours.

• If the initial 2.5 mg dose is not effective, your doctor may recommend subsequent episodes may be treated with a 5 mg dose.
• People with kidney problems should not exceed 2.5 mg (one tablet) per day.
• Zolmitriptan should not be used to prevent migraine—it is designed for relief during an active episode.

How and When to Take It  (7)

• Within the limits of safe dosing frequency, take as early as possible during a migraine attack. While taking a triptan early is associated with improved benefit, it can continue to have benefit if you are not able to take it early
• Swallow tablets whole with a full glass of water, with or without food.
  
• If the migraine returns after initial relief, a second dose may be taken after 2 hours.
  
• If zolmitriptan does not provide relief, do not exceed the recommended dosing in a 24 hour period. You can take it for future episodes or you can consult your doctor for alternative options.
  
• Do not use other migraine-specific medications (e.g. a different triptan, ergotamine, dihydroergotamine or methysergide) within 24 hours of zolmitriptan. 

Other Information (7)

• Not every triptan works for everyone. In those people for whom Zolmitriptan is effective, it works for migraine with, or without aura, and in menstrually associated migraine.
• When assessing how effective any new acute treatment is for your migraine, it is helpful to examine whether the therapy works over an average of three individual attacks.
• The half-life of zolmitriptan is approximately 3 hours. Most of the medication (60%) is processed by the liver and excreted in urine.
• If nausea prevents you from swallowing tablets, speak to your doctor about combining with anti-nausea medications, or other options
• This medication has other formulations not currently available in Australia: a nasal spray, an orally disintegrating tablet (ODT), and a subcutaneous injection.

Triptans are considered safe for long-term use when taken appropriately. The key concern is how frequently they are used—not how long someone uses them over time. In some cases, triptans may become less effective without a clear reason, which can also happen with other migraine treatments. (2)

If you take too much zolmitriptan, you may need urgent medical attention even if there are no signs of discomfort or poisoning. In this case, you should immediately phone the Poisons Information Centre (13 11 26), contact your doctor, or go to the emergency department at your nearest hospital (7).

How effective is Zolmitriptan?

Zolmitriptan has been well studied in both short-term and long-term trials  for the acute treatment of migraine, with over 4,000 people participating in clinical trials. Across studies, both the 2.5 mg and 5 mg doses were found to be equally effective, providing relief within two hours for around 60–65% of people, and complete relief for up to 47%. Nausea was less common with zolmitriptan than with placebo. (7)

The 10 mg dose may offer slightly more benefit, but it also increases the risk of side effects. For this reason, 2.5 mg is generally recommended as a starting dose, with the option to increase to 5 mg if needed.

In long-term studies, including the International 311C90 study, over 80% of migraine episodes responded well, 67% of people experienced success in 80–100% of their treated episodes over time, and most people experienced consistent results over time. (8)

The nasal spray version, which is not available in Australia, acts faster than tablets, particularly in the first two hours, but doesn’t increase the chance of being completely pain-free. About 1 in 7 people using the nasal spray reported taste disturbances. Across all forms, side effects were usually mild and short-lived. (9)

Overall, zolmitriptan has been shown to be a fast-acting, well-tolerated and effective acute treatment option for many people living with migraine, with consistent results across both in single and repeated use.

One study evaluated the efficacy of different types and formulations of triptans in a systematic review and meta-analysis (10). The table below shows the proportion of patients achieving specific pain outcomes for zolmitriptan compared to placebo, paracetamol and non-steroidal anti-inflammatories (NSAIDs) (10).

If Zolmitriptan doesn’t work for you, it may be worth trying a different triptan. Most people with migraine will respond to at least one type of triptan medication, with trials suggesting that it is worth trying other types if the first one doesn’t work (11). Even though all triptans work broadly in the same way, they each have some inherent differences and people may also respond differently to the same triptan. These factors will play a role in which triptan works for you.

Side effects

Zolmitriptan is well tolerated. Most side effects of zolmitriptan are mild, short-lived, and occur within four hours of taking a dose. Side effects were similar for either the 2.5mg or 5mg doses. Serious side effects are rare, even with repeated use.(7)

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Seek emergency care immediately if you experience chest pain, breathing difficulty, signs of stroke, severe allergic reaction, or other serious symptoms.

You can report side effects to your doctor or via the Therapeutic Goods Administration: www.tga.gov.au/reporting-problems

Warnings & Risks

Medication overuse headache or “poorly controlled migraine”

Zolmitriptan is not addictive, but it is associated with medication overuse headache (MOH). MOH may occur when acute headache medications, such as pain relievers or triptans, are used too frequently or in excessive amounts, resulting in a worsening of headache symptoms and frequency. This can create a vicious cycle—where increased medication use leads to more frequent headaches, reduced treatment effectiveness, and the potential development of chronic daily headache. MOH not only increases migraine frequency but can also make both acute and preventive treatments less effective over time.

The safe limit for avoiding MOH while on zolmitriptan (or any other triptans) is to take the medication on fewer than 10 days during any month, or 30 day period.  If you experience your migraine episodes on more than four days per month, it is important to speak to your doctor about whether preventative therapy may be appropriate, to reduce the frequency of your episodes and allow you to take your acute treatment when you need it.

However, it’s important to ensure that your acute medication is effective—meaning it provides meaningful relief during an episode. Poorly managed or frequent episodes can contribute to migraine chronification, as the underlying brain changes that drive migraine may continue if episodes are not treated effectively. Early and effective intervention is key. (12)
In clinical and research settings, a medication is typically considered effective if it results in complete pain relief within two hours of use.

Please check with your doctor or pharmacist how often it is appropriate for you to take zolmitriptan, including if you are taking it with over-the-counter pain medicines.

Health conditions that may not be appropriate for zolmitriptan

All triptans, including zolmitriptan, work by narrowing blood vessels. Because of this, they may not be suitable for people with certain health conditions. Triptans should generally be avoided by people with vascular disease (including stroke, previous heart attacks or ischaemic heart disease), uncontrolled high blood pressure, or hemiplegic migraine. (13)

Zolmitriptan is also not suitable for people who are allergic to it or to any of the ingredients in the medication, such as lactose. If you have allergies or experience symptoms after taking zolmitriptan, stop the medication and seek medical advice. You can check the full ingredient list in the Consumer Medicine Information leaflet.

Some people may need extra checks before using zolmitriptan, such as heart tests, especially if there are signs or symptoms that suggest cardiovascular concerns.

Specific warnings include (5):

• Severe liver or kidney problems
• High blood pressure that is difficult to treat
• If you have, or have had, heart or blood vessel disease or signs of these conditions, including: 
  • Angina, stroke, heart attack
  • Dizzy or fainting spells
  • Shortness of breath
  • Pains in the chest
  • Cold hands or feet
  • Pain in the calves when walking
• If you have risk factors for coronary artery disease (CAD) such as high blood pressure, high cholesterol, smoking, obesity, diabetes, family history of CAD, post menopause in females and age over 40 years in males.

You should speak to your doctor if:

• You have any of the above
• You are pregnant, planning a pregnancy, or breastfeeding
• You are allergic to zolmitriptan or other ingredients in the medication

Your doctor can help determine if zolmitriptan is safe and appropriate for you. In some cases, they may recommend tests or alternative treatment options.

Interactions

Zolmitriptan administration is contraindicated with other 5HT1D receptor agonists (triptans), or with monoamine oxidase inhibitors or ergotamine. The drug is not affected by paracetamol, metoclopramide or pizotifen.

Zolmitriptan may be more suitable than sumatriptan for people with allergies to sulfonamides as it does not have a sulfonamide side chain.

There is minimal risk of serotonin syndrome with triptans and SSRIs/SNRIs; such interactions are rare, however it is important to speak to your doctor, particularly if you take higher doses or multiple serotonergic medications.(2)

Some medicines interact with others, affecting how well they work or putting health at risk. It is very important that you always tell your doctor and pharmacist about all medications you are taking, including non-prescription medications, natural therapies and vitamins.

Please also refer to the relevant Consumer Medicine Information leaflet for further details. (7)

Further information & resources

If you would like to learn more about migraine or different treatment options, you may find the following articles helpful.

• Migraine – a comprehensive article about migraine symptoms, causes, treatments, and more.
• Acute Migraine Medication – article summarising other types of acute migraine medication, including a general overview of other triptans. 
• Treatment directory – overview article including a brief explanation of the medications available to treat migraine and different classes of treatment.
• Sumatriptan – medication review for sumatriptan, another medication in the same class as zolmitriptan.
• Understanding and Managing the Psychological Impact– article exploring the less visible impacts of living with migraine, offers practical, evidence-informed strategies to help people living with migraine not just cope, but live well
• Strategies to Help Prevent the Progression from Episodic to Chronic Migraine – article exploring the factors that play a role in migraine chronification and strategies for prevention.

References

1. WJ Becker, 2015, Acute Migraine Treatment in Adults. https://doi.org/10.1111/head.12550 
2. Peter Goadsby, The Latest New Treatment Innovations. Migraine World Summit, 2020. Accessed 2025 from:  https://migraineworldsummit.com/talk/the-latest-new-treatment-innovations/ 
3. Patricia Pozo-Rosich,  Triptans Today: Their Role in Contemporary Migraine Treatment. Migraine World Summit, 2025. Accessed 2025 from: https://migraineworldsummit.com/talk/triptans-today-their-role-in-contemporary-migraine-treatment/ 
4. B Jenkins, 2020, Migraine management. https://doi.org/10.18773/austprescr.2020.047   
5. G Sandrini et al, 2009, Eletriptan. DOI: 10.1517/17425250903410226
6. Pharmaceutical Benefits Scheme. Accessed 2025, from: https://www.pbs.gov.au/medicine/item/8266C
7. Therapeutics Goods Administration, Australian Government, Consumer Medicine Information. Accessed 2025 from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=zolmitriptan
8. Zagami AS. 311C90: long-term efficacy and tolerability profile for the acute treatment of migraine. International 311C90 Long-Term Study Group. Neurology. 1997 Mar;48(3 Suppl 3):S25-8. doi: 10.1212/wnl.48.3_suppl_3.25s
9. Bird S, Derry S, Moore RA. Zolmitriptan for acute migraine attacks in adults. Cochrane Database Syst Rev. 2014 May 21;2014(5):CD008616. doi: 10.1002/14651858.CD008616.pub2
10. C Cameron et al, 2015, Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. doi: 10.1111/head.12601
11. B Gilmore & M Michael, 2011, Treatment of Acute Migraine Headache. PMID: 21302868. Retrieved from: https://pubmed.ncbi.nlm.nih.gov/21302868/ 
12. Ailani Jessica: “Controlling chronic migraine”. Migraine World Summit, 2024. Accessed 2025 from: https://migraineworldsummit.com/talk/controlling-chronic-migraine/ 
13. Robbins, M., MD. (2017). Planning for Pregnancy With Migraine. Migraine World Summit. Retrieved 2025 from: https://migraineworldsummit.com/triptans-for-migraine/